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ABSTRACT
Bladder cancer (BC) is the most frequent malignancy of the urinary tract with a 
high incidence in men and smokers. Currently, there are no non-invasive markers useful 
for BC diagnosis and subtypes classification that could overcome invasive procedures 
such as cystoscopy. Dysregulated miRNA profiles have been associated with numerous 
cancers, including BC. Cell-free miRNAs are abundantly present in a variety of biofluids 
including urine and make them promising candidates in cancer biomarker discovery.
In the present study, the identification of miRNA fingerprints associated with 
different BC status was performed by next-generation sequencing on urine samples 
from 66 BC and 48 controls. Three signatures based on dysregulated miRNAs have 
been identified by regression models, assessing the power to discriminate different 
BC subtypes. Altered miRNAs according to invasiveness and grade were validated by 
qPCR on 112 cases and 65 controls (among which 46 cases and 16 controls were an 
independent group of subjects while the rest were replica samples).
The area under the curve (AUC) computed including three miRNAs (miR-30a-5p, 
let-7c-5p and miR-486-5p) altered in all BC subtypes showed a significantly increased 
accuracy in the discrimination of cases and controls (AUC model = 0.70; p-value = 0.01).
In conclusions, the non-invasive detection in urine of a selected number of miRNAs 
altered in different BC subtypes could lead to an accurate early diagnosis of cancer and 
stratification of patients.
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INTRODUCTION
Bladder cancer (BC) is among the most frequent 
malignancies worldwide, with an estimated 429,000 new 
cases in 2012 [1]. BC is a highly heterogeneous disease. 
The largest portion of cases (70%) is non-muscle-invasive 
BC (NMIBC), confined to mucosa or submucosa and with 
superficial, non-infiltrating lesions. The remaining subset 
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of cases is classified as muscle-invasive BC (MIBC) [2]. 
There is a quite high percentage of NMIBC (50–70%) that 
will recur, and roughly 10–30% will progress to MIBC [3]. 
BC screening and early diagnosis have primary 
importance in improving survival and quality of life of 
patients. Urine cytology is currently the most commonly 
non-invasive test used for BC detection but is of limited 
value owing to its poor sensitivity, especially for 
low-grade lesions [4]. Cystoscopy-guided biopsy for 
histological evaluation can offer high diagnostic accuracy 
but it is invasive and inconvenient for patients. BC is also 
among the most expensive cancers and poses a significant 
economic and social challenge, as the high rate of 
recurrences requires continuous cystoscopic surveillance 
[5]. Hence, non-invasive and more sensitive molecular 
biomarkers are needed to improve current strategies for 
the detection and monitoring of this cancer,  particularly 
in patients` biofluids [6, 7].
microRNAs (miRNAs) are a class of small non-
coding RNAs that act as post-transcriptional regulators in 
gene expression silencing by binding to complementary 
messenger RNA. Deregulated miRNA profiles have been 
associated with numerous cancers, including BC [8]. 
Cell-free miRNAs are abundantly present in a variety of 
biofluids including plasma, saliva, and urine [9–11]. The 
easy accessibility of several biofluids and the remarkable 
stability of cell-free miRNAs make them promising 
candidates in cancer biomarker discovery [7].
In the last years, the research on BC has focused 
on urinary markers and proposed several candidates but 
only some were validated in independent populations [12]. 
Frequently, studies were based on heterogeneous groups of 
patients, with no attention to the subtype characterization. 
Moreover, no studies were conducted to profile urinary 
miRNAs at whole miRNome level using deep sequencing 
techniques [13].
In the present study, we investigated urinary 
miRNA profiles in association with BC and different 
clinicopathological subtypes by next-generation 
sequencing (NGS). Candidate miRNAs were validated by 
real-time quantitative PCR (qPCR). The most interesting 
miRNAs were included in a model to test their power in 
predicting BC.
RESULTS
Discovery 
In total, 114 samples (from 66 BC cases and 48 
controls) were used in the analyses. Among cases, ten 
were diagnosed MIBC while 56 were NMIBC (39 G1 + 
G2 and 17 G3) (Table 1).
Details about the sample features are reported in 
Supplementary Table 1 and Supplementary Results. The 
analysis of the raw reads has led to the definition of the 
starting count matrix composed of 114 samples and 1822 
miRNAs having at least one read in one sample (see 
Supplementary Material and Methods). However, in the 
analyses of the Discovery phase, only miRNAs having at 
least 20 counts considering all samples (1787 miRNAs out 
of 1822) were included.
In the comparison between NMIBC G1 + G2 and 
controls, 98 differentially expressed miRNAs were found, 
and 14 of them had high read abundance (from hereby 
called DEmiRNAs). Five miRNAs (miR-30a-5p, miR-
205-5p, miR-584, let-7c and miR-7706) were associated 
with a Predictive Power (PP) higher than 0.7 by logistic 
regression analysis (PPmiRNAs) (Supplementary Table 
2A). Following the criteria described in Supplementary 
Material and Methods, seven candidates as NMIBC G1 + 
G2 biomarkers were singled out (reported in Table 2). Plot 
counts are shown in Supplementary Figure 1.
In the second comparison (NMIBC G3 vs. 
controls), 263 DEmiRNAs and 61 PPmiRNAs were 
found (Supplementary Table 2B). For the Validation/
Replica phase, we selected three miRNAs in common 
between DEmiRNAs and PPmiRNAs and 12 additional 
candidate miRNAs inspecting the plot counts (miR-
30a-5p, let-7c, miR-486-5p, miR-183-5p, miR-185-5p, 
miR-106b-3p, miR-98-5p, miR-4448, miR-30c-2-5p, 
miR-151a-3p, miR-200c-3p, miR-21-5p, miR-10b-5p, 
miR-224-5p, and mir-148b-3p) as candidate NMIBC 
G3 biomarkers (Table 2). Plot counts are shown in 
Supplementary Figure 2.
In the final comparison, MIBC versus controls, 
11 DEmiRNAs and 48 PPmiRNAs were found 
(Supplementary Table 2C). We selected ten miRNAs as 
candidate MIBC biomarkers (Table 2). Plot counts of these 
miRNAs are reported in Supplementary Figure 3. 
Out of seven miRNAs selected for NMIBC G1 + G2, 
15 for NMIBC G3 and 10 for MIBC, eight miRNAs were 
in common between the different BC subtypes with three 
of them in common among all three groups. Finally, 21 
miRNAs were selected for the Replica/Validation phase. 
The complete list of all candidate miRNA biomarkers for 
each comparison is reported in Table 2. Heatmaps for all 
miRNAs emerging from all comparisons are reported in 
Supplementary Figure 4.
To select proper endogenous controls for qPCR 
normalization, data from NGS were analysed adapting 
the pipeline developed by Eisenberg and Levanon [14]. 
Two reference genes (miR-28-3p and miR-361-3p) 
were responding to the selection criteria and were 
employed as endogenous controls in the qPCR analyses.
Replica/Validation 
Twenty-one candidate miRNAs from the Discovery 
phase were validated by qPCR on the same set of BC cases 
and controls employed in the small RNA-seq analyses 
(Replica set) and on urine samples from additional 46 BC 
cases (43 G1 + G2 and 3 G3) and 16 controls (Validation 
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Table 1: Baseline patient and tumor characteristics of the samples included in the study
Discovery (n) Validation (n) Overall (n)
Cases (66) Controls (48) Cases(46)
Controls
(16)
Cases
(112)
Controls
(65)
Age Mean (median) 64.27 (65.02) 64.64 (65.60) 64.63 (66.83) 65.14 (70.25) 64.42 (65.89) 64.76 (66.53)
Intervals 44.92–74.10 46.44–74.91 46.78–74.64 41.92–74.49 44.92–74.64 41.92–74.91
Smoking non smokers 7 5 3 6 10 11
former smokers 34 26 22 6 56 32
current smokers 25 18 21 3 46 21
n.a. 0 0 0 1 0 1
Grade# G1 14 16 30
G2 25 27 52
G3 27 3 30
G# High grade 41 14 55
Low grade 25 32 57
Tumor Stage Tis 3 1 4
Ta 29 35 64
T1 24 8 32
≥T2 10 0 10
TX 0 2 2
Tumor Type* NMIBC 56 46 102
MIBC 10 0 10
Risk#* 1 11 15 26
2 18 22 40
3 26 9 35
MIBC 10 0 10
n.a. 1 0 1
Recurrences yes 25 15 40
no 41 31 72
Progression yes 2 0 2
no 64 46 110
Status Alive 58 44 102
Dead 8 2 10
*According to EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013; European 
urology. 2013; 64:639–653.
#According to Cheng L. Cancer: 2000; 88:1513–6. and Montironi R. Lopez-Beltran A. International Journal of Surgical 
Pathology. 2005; 13:143–53. 
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Table 2: List of all candidate miRNAs from the discovery phase stratified for BC invasiveness that were selected for 
replica/validation phase
Mean read counts log2 Fold Change adj P (FDR) PP
Candidate miRNAs for MIBC
amiR-21-5p 29223 1.42 0.01 0.85
amiR-106b-3p 130 2.53 0.00 0.85
bmiR-30a-5p 19453 –1.80 0.05 0.85
blet-7c-5p 1497 –1.62 0.02 0.85
bmiR-486-5p 819 3.68 0.01 <0.70
cmiR-205-5p 376 2.97 0.00 0.9
miR-451a 1004 3.40 0.04 <0.70
miR-25-3p 588 1.99 0.02 <0.70
miR-7-1-5p 518 3.32 0.05 0.85
miR-146a-5p 420 2.49 0.04 <0.70
Candidate miRNAs for NMIBC G1 + G2 
dmiR-30c-2-5p 2106 –0.73 0.00 <0.70
dmiR-151a-3p 2873 0.34 0.02 <0.70
bmiR-30a-5p 27229 –0.63 0.00 0.73
blet-7c-5p 2644 –0.43 0.04 0.71
bmiR-486-5p 1868 1.94 0.02 <0.70
cmiR-205-5p 479 1.82 0.00 0.73
let-7i-5p 5038 0.55 0.03 <0.70
Candidate miRNAs for NMIBC G3 
amiR-21-5p 38624 0.87 0.03 0.76
amiR-106b-3p 184 2.30 0.00 0.88
bmiR-30a-5p 29232 –1.67 0.00 0.76
blet-7c-5p 2939 –1.17 0.03 <0.70
bmiR-486-5p 2918 3.14 0.00 <0.70
dmiR-30c-2-5p 2241 –1.47 0.01 <0.70
dmiR-151a-3p 3884 0.51 0.03 <0.70
miR-10b-5p 28018 –1.88 0.00 0.85
miR-148b-3p 660 0.95 0.00 0.85
miR-183-5p 1414 1.50 0.00 <0.70
miR-185-5p 381 2.10 0.00 0.76
miR-200c-3p 9145 1.11 0.00 0.76
miR-224-5p 488 2.97 0.00 0.79
miR-4448 7834 –2.27 0.01 <0.70
miR-98-5p 459 1.01 0.01 0.79
Abbreviations: FDR false discovery rate, PP predictive power, MIBC muscle-invasive bladder cancer, NMIBC non-muscle 
invasive bladder cancer.
amiRNAs in common between NMIBC G3 and MIBC.
bmiRNAs in common among NMIBC G1 + G2, NMIBC G3, and MIBC.
cmiRNAs in common between NMIBC G1 + G2 and MIBC.
dmiRNAs in common between NMIBC G1 + G2 and NMIBC G3.
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set). miR-28-3p and miR-361-3p were also analyzed 
in the Replica/Validation as endogenous controls for 
normalization. miR-4448 was not detected by qPCR. 
The results of Replica/Validation are reported in 
Table 3 and in Supplementary Table 3. The normalized 
expression levels from qPCR showed patterns comparable 
to those provided by sequencing, although with different 
significance. For NMIBC G1 + G2 patients, there was a 
significant down-regulation of miR-30c-2-5p (p = 0.02) and 
up-regulation of miR-205-5p (p < 0.001) in cases compared 
to controls (Replica set; Table 3). In the overall NMIBC 
G1 + G2 cases (Replica + Validation) when compared 
with all controls, only miR-205-5p remained significantly 
upregulated (p = 0.0001), together with miR-486-5p 
(p = 0.02) and let-7i-5p (p = 0.03) that were significantly 
up-regulated in the Discovery phase.
Among NMIBC G3 patients and controls, out the 
15 miRNAs tested by qPCR, ten resulted significantly 
differentially expressed in both Replica and Replica + 
Validation sets. More specifically, miR-21-5p, miR-
106b-3p, miR-486-5p, miR-151a-3p, miR-200c-3p, 
miR-183-5p, miR-185-5p, and miR-224-5p (p-value in 
Replica + Validation set ranging from 1.94 × 10–6 to 0.02) 
resulted upregulated in NMIBC G3, while miR-30c-2-
5p and miR-10b-5p were down-regulated (p = 0.02 and 
p = 0.005, respectively; Table 3). 
For MIBC, miR-486-5p, miR-205-5p, miR-451a, 
miR-25-3p, and miR-7-1-5p resulted significantly 
upregulated in comparison to controls (p-value ranging 
from 0.001 to 0.02) while miR-30a-5p (p = 0.006) was 
down-regulated (Replica + Validation set, Table 3). Results 
from small RNA-seq for MIBC were further compared 
with data from the The Cancer Genome Atlas (TCGA) 
dataset [15]. Out of 324 MIBC cases of Caucasian descent 
with available miRNA expression quantification, only 16 
had both “Solid Tissue Normal” and “Primary Tumor” 
samples available. Seven miRNAs found in the Discovery 
phase for MIBC were also significantly differentially 
expressed in the same direction in TCGA dataset (Table 4).
We observed a significant trend of increasing/
decreasing expression levels from healthy controls to 
MIBC patients for two out of three miRNAs (miR-
30a-5p and miR-486-5p) that were tested in the 3 BC 
subtypes (p = 0.006 and 0.01, respectively). Significant 
trends were observed also for some miRNAs in common 
between NMIBC G1 + G2 and G3 (miR-30c-2-5p; 
p = 0.002), between NMIBC G1 + G2 and MIBC (miR-
205-5p; p = 0.009) and NMIBC G3 and MIBC (miR-
106b-3p; p = 0.01) (Supplementary Table 4; Figure 1). 
We conducted the same analyses considering only BC 
cases and we confirmed a significant decreasing trend for 
miR-10b-5p, miR-98-5p, miR-148-3p, miR-30a-5p and 
miR-30c-2-5p (p-value from 0.002 to 0.04).
Finally, we designed two models: Model 0 including 
traditional BC risk factors (age and smoking status) and 
Model 1 (i.e., Model 0 plus miR-30a-5p, let-7c-5p and 
miR-486-5p expression levels in the three BC subtypes). 
Model 1 showed a statistically significant improvement 
in the discrimination of cases and controls in comparison 
with Model 0 (Area under the ROC curve (AUC) model 
0 = 0.57, 95% CI: 0.49–0.67; AUC model 1 = 0.70, 
95% CI: 0.63–0.78, DeLong’s test p = 0.01, Figure 2). 
Considering the 3 BC subgroups separately and including 
in each Model 1 only significant DEmiRNAs from Table 
3, we observed a statistically significant improvement 
in the discrimination of for each subgroup of cases and 
controls (for NMIBC G1 + G2 AUC model 0 = 0.62; AUC 
model 1 = 0.73, DeLong’s test p = 0.02; for NMIBC G3, 
AUC model 0 = 0.57; AUC model 1 = 0.95, DeLong’s test 
p = 1.15 × 10–6; for MIBC, AUC model 0 = 0.64; AUC 
model 1 = 0.99, DeLong’s test p = 2.27 × 10–5) (data not 
shown).
Each of the selected miRNAs shows a large number 
of validated target genes (ranging from 66 to 913) which 
resulted significantly involved in several important KEGG 
(Kyoto Encyclopedia of Genes and Genomes) pathways 
such as MAPK signaling (for let-7c-5p, miR-10b-5p, 
miR-200c-3p), ErbB signaling pathway (for let-7c-5p, 
miR-106b-3p), and pathways in cancer/bladder cancer. 
Specifically, target genes of miR-30a-5p, miR-486-5p, 
miR-30c-2-5p, miR-205-5p, and miR-106b-3p whose 
expression levels showed a trend from healthy controls to 
MIBC patients displayed an over-representation in several 
KEGG pathways such as “Pathways in cancer_Homo 
sapiens” (hsa05200; adj p = 1.05 × 10–7), “MicroRNAs 
in cancer_Homo sapiens” (hsa05206; adj p = 2.97 × 10–7) 
and “Bladder cancer_Homo sapiens” (hsa05219; adj p = 
3.38 × 10–5).
DISCUSSION
In the present study, we tested urinary miRNAs 
as non-invasive biomarkers for BC at diagnosis, with 
a potential application also for patients follow up. It 
was possible to define and validate a panel of miRNA 
markers that can accurately detect BC and differentiate 
its subtypes. Moreover, most of the miRNAs identified 
in the discovery set by NGS were also confirmed in the 
Replica + Validation set by qPCR.
Individual miRNA profiles may provide a low 
accuracy as cancer biomarkers, mostly due to the 
multifactorial nature of BC but also the large number 
of targets for a single miRNA [16]. Therefore, the 
combination of specific miRNA profiles may provide 
more robust results. Introducing miR-30a-5p, let-7c-5p 
and miR-486-5p altered in the 3 BC subtypes in a model 
for case-control discrimination, we observed a statistically 
significant improvement in AUC discrimination between 
BC and controls (from 50% to 70%). Currently, there 
are no validated non-invasive markers able to identify 
Oncotarget20663www.oncotarget.com
Table 3: miRNAs analysed in the replica/validation phase by qPCR and stratified for BC invasiveness and grade
  Replica Replica/Validation
 miRNA Log2 Fold Change P adj P
Log2 Fold 
Change P adj P
MIBC amiR-21-5p 0.65 0.309 0.386 0.73 0.271 0.338
amiR-106b-3p 1.33 0.069 0.116 1.58 0.054 0.107
bmiR-30a-5p –2.43 0.002 0.011 –2.12 0.006 0.017
blet-7c-5p –1.29 0.144 0.205 –1.04 0.234 0.312
bmiR-486-5p 2.55 0.026 0.058 2.75 0.017 0.038
cmiR-205-5p 1.84 0.005 0.017 1.92 0.012 0.029
miR-451a 3.13 0.011 0.031 3.57 0.004 0.014
miR-25-3p 1.97 0.005 0.017 2.21 0.004 0.014
miR-7-1-5p 2.49 0.002 0.011 2.74 0.001 0.012
 miR-146a-5p 1.00 0.109 0.168 1.14 0.131 0.193
NMIBC 
G1 + G2
dmiR-30c-2-5p –1.08 0.022 0.144 –0.58 0.149 0.248
dmiR-151a-3p –0.26 0.494 0.657 0.37 0.265 0.353
dmiR-30a-5p –0.52 0.304 0.656 –0.28 0.482 0.508
blet-7c-5p –0.18 0.764 0.858 0.25 0.553 0.553
bmiR-486-5p 1.67 0.059 0.197 1.63 0.017 0.073
cmiR-205-5p 1.76 0.000 0.007 1.60 0.000 0.002
 let-7i-5p 0.31 0.427 0.656 0.76 0.026 0.076
NMIBC G3 amiR-21-5p 1.36 0.005 0.008 1.29 0.007 0.011
amiR-106b-3p 1.67 0.001 0.002 1.94 0.000 0.001
bmiR-30a-5p –0.97 0.127 0.149 –0.78 0.178 0.210
blet-7c-5p 1.25 0.088 0.110 1.13 0.097 0.121
bmiR-486-5p 3.13 0.001 0.002 3.37 0.000 0.001
dmiR-30c-2-5p –1.56 0.001 0.002 –1.19 0.019 0.027
dmiR-151a-3p 1.22 0.001 0.002 1.41 0.001 0.002
miR-200c-3p 1.53 0.000 0.001 1.63 0.000 0.001
miR-4448 na  na
miR-183-5p 1.96 0.000 0.000 1.98 0.000 0.000
miR-185-5p 0.86 0.015 0.021 0.87 0.022 0.029
miR-98-5p 0.34 0.473 0.526 0.00 0.995 0.995
miR-148b-3p 0.09 0.887 0.887 –0.03 0.951 0.995
miR-10b-5p –1.69 0.018 0.024 –1.64 0.005 0.008
 miR-224-5p 2.76 0.000 0.000 2.97 0.000 0.000
Significant results in bold. Abbreviations: FDR false discovery rate, PP predictive power, MIBC muscle-invasive bladder 
cancer, NMIBC non-muscle invasive bladder cancer.
amiRNAs in common between NMIBC G3 and MIBC.
bmiRNAs in common among NMIBC G1 + G2, NMIBC G3, and MIBC.
cmiRNAs in common between NMIBC G1 + G2 and MIBC.
dmiRNAs in common between NMIBC G1 + G2 and NMIBC G3.
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Table 4: DEmiRNAs found in the discovery phase for MIBC analysed in the TCGA dataset
ID miRNA 
(present study) ID miRNA (TCGA)
Mean read 
counts
log2 Fold 
Change
adj P 
(Bonferroni)
adj P
(FDR)
miR-30a-5p miR-30a 179888 –2.496 5.28045E–21 1.26467E–19
miR-21-5p miR-21 854585 1.717 9.28451E–09 1.9336E–08
miR-106b-3p miR-106b 2614 1.091 9.0971E–06 7.14346E–06
let-7c-5p let-7c 27205 –1.896 0.0002 8.76786E–05
miR-7-1-5p miR-7-1 93 0.968 0.0005 0.0002
miR-205-5p miR-205 25289 1.956 0.0049 0.0015
miR-25-3p miR-25 47417 0.656 0.0801 0.0165
miR-486-5p# miR-486-2# 475 –0.645 1.8177 0.2466
miR-486-5p# miR-486-1# 473 –0.593 2.3635 0.3102
miR-451a miR-451a 3849 –0.221 6.7117 0.7409
miR-146a-5p miR-146a 482 –0.058 8.8212 0.9087
Abbreviations: FDR false discovery rate, MIBC muscle-invasive bladder cancer.
Significant results in bold.
#for this miRNA it was not possible to distinguish the locus.
Figure 1: Box plots of expression levels of selected miRNAs with a significant trend (adjusted p-value < 0.05) from 
healthy controls to MIBC patients.
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BC presence and subtypes. Therefore, the diagnosis and 
follow-up still rely on cystoscopies, with a huge burden for 
the health system and inconvenience for BC patients [5, 6]. 
Recently, some urine-based tests have been approved for 
the clinical practice. However, there is still large disparity 
of sensitivity and specificity across different BC grades 
with a still sub-optimal clinical utility [17, 18]. Since urine 
is in direct contact with the tumor, it represents an ideal 
source for investigation of non-invasive BC biomarkers. 
Our model based on specific miRNA profiles might 
represent a promising advancement in the non-invasive 
diagnosis of BC. Even if an accuracy of 0.7 remains still 
sub-optimal for a definitive implementation in the clinical 
practice, it surely constitutes a step in the right direction 
towards a less aggressive follow-up of BC patients.
Several DEmiRNAs have  been repeatedly 
associated with BC in tissues but in general on small-
size study populations [13, 19]. Interestingly, 6 miRNAs 
that we have also validated (miR-205-5p, miR-25-3p, 
miR-7-1-5p, miR-183-5p, miR-185-5p and miR-224-5p) 
were reported dysregulated by BC tumor tissues versus 
normal bladder mucosa by the Bladder Cancer Cluster 
Knowledge Base (http://www.bccluster.org/). This is of 
particular importance since the expression levels measured 
in bladder tissues and urine showed the same behaviour, 
highlighting the importance of these miRNAs as possible 
biomarkers for BC diagnosis. 
The studies so far have been based on a candidate-
driven approach (by qPCR) and relatively small sample 
sets, providing often mixed results (reviewed by [20] and 
[13]). Moreover, there is still ambiguity regarding the best 
type of specimen to use for miRNA investigation among 
whole urine, sediments, supernatant or exosomes. The 
majority of urinary miRNAs originates from renal and 
urethral cells and analysis of these cells can provide a 
measure of the health status of the excretory system [21]. 
A meta-analysis reported that urine supernatant-based 
studies are more reliable than urine sediment-based assay 
or voided urine [16]. In support of the urine supernatant-
based approach, when miRNA expression profiles in four 
biological specimens (including tumor tissues and cell-
free urine) were compared, among the top 25 up-regulated 
miRNAs in NMIBC there were 13 species that resulted 
in common among cell-free urine and cancer tissues 
[18]. Interestingly, four of those up-regulated miRNAs 
were also found in our study. Comparing our results to 
those reported from candidate miRNA approach studies 
(reviewed by [16]), only the up-regulation of miR-183-5p 
was confirmed [22]. 
We are aware that our study is not devoid of 
limitations, such as the absence of an independent set of 
urine samples from MIBC cases, and the size of the study 
population in the Replica + Validation phase. However, 
seven of the miRNAs belonging to the signature for MIBC 
Figure 2: Area under the ROC curve (AUC) for Model 0 (including age and smoking habit as risk category; in grey) 
and Model 1 (including Model 0 plus expression levels of miR-30a-5p, let-7c-5p and miR-486-5p; in black).
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were also significantly differentially expressed in the 
same direction in the TCGA dataset (on bladder tissues), 
confirming that molecular alterations in BC tissues are 
mirrored in urine. Moreover, we analyzed our cohort using 
an up-to-date deep sequencing technology that permits the 
more complete overview of the whole miRnome available 
at the present without the known limitations of arrays or 
candidate miRNA approach.
To the best of our knowledge, this is the first study 
that profiled miRNAs in urine of BC patients by NGS. We 
attempted to implement a model and a pipeline for miRNA 
data processing since, although some guidelines have 
been published [23–25], currently there is no standardized 
procedure. 
Part of the observed discrepancies in the 
outcomes from different studies on urine so far, based 
on microarrays or qPCR, may be due to inconsistencies 
in name usage when referring to a list of expressed, 
differentially expressed or selected miRNAs. This might 
lead to mistakes in name-driven comparisons of miRNA 
lists (such as signatures) or meta-analyses from diverse 
sources (papers, databases). Moreover, probes to detect 
mature miRNA expression in general refer to or are 
designed on different releases of miRBase and do not 
undergo a regular re-annotation according to its updates. 
Finally, a substantial portion of publications relies on 
human miRNA names without disclosing their genomic 
annotation, contributing to uncertainties in the literature 
[26]. These limitations have precluded the clinical 
translation of biomarkers studies in the management of 
BC [27]. However, with the implementation of miRNA 
sequencing, the analyses procedure can be repeated over 
time with the most updated mapping, thus overcoming 
this problem. In the present study, we have paid particular 
attention to a proper characterization of miRNA precursors 
and correct annotation of miRNA species.
Another key issue for the comparison of miRNA 
expression levels is the selection of miRNAs found 
to be largely invariant in a sample set (i.e. endogenous 
controls). As there is no consensus on suitable control for 
urine testing, it is suggested that quantification should 
be performed with an equal amount of starting total 
RNA or adopting other stably expressed small RNAs as 
normalizers. In the present study, we suggested a possible 
approach to identify the possible internal candidate 
endogenous controls from NGS data. 
The adoption of deep sequencing has provided a 
broad overview of the altered expressed miRNAs in urine 
while the unsupervised classification algorithm and the 
computation of the PP have identified a set of putative 
miRNAs as urinary biomarkers. Once confirmed in 
additional studies on larger populations of BC cases and 
controls, our panel of miRNAs detectable in urine may 
become an effective and reproducible molecular test.
MATERIALS AND METHODS
Patients
The study population consisted of men recruited 
in the Turin Bladder Cancer Study (TBCS) [28, 29]. All 
subjects provided written consent to participate to the 
study, according to the Helsinki declaration. The study 
was approved by the Interhospital Ethical Board of San 
Giovanni Battista/C.T.O./C.R.F./Maria Adelaide hospitals 
(Turin, Italy) and the Institutional Review Boards of the 
Human Genetics Foundation. Details on patients and 
controls are in Table 1 and Supplementary Material and 
Methods.
RNA extraction and small RNA-sequencing 
(small RNA-seq)
The protocol for urine collection, storage and 
processing together with library preparation is described in 
Supplementary Material and Methods and in [30]. Briefly, 
total RNA was extracted from urine supernatant samples 
(see [31]) using the Urine microRNA Purification kit 
(Norgen Biotek, Canada), according to the manufacturer’s 
standard protocol.
Small RNA transcripts were converted into barcoded 
cDNA libraries with the NEBNext Multiplex Small RNA 
Library Prep Set for Illumina (New England BioLabs, 
USA) and run on Illumina HiSeq2000 platform (Illumina, 
USA).
miRNA quantification by qPCR
Candidate miRNA biomarkers were validated in 
independent urine samples using the miRCURY LNA™ 
Universal RT microRNA PCR system (Exiqon, Denmark). 
Reverse transcription (RT) was performed using the 
Universal cDNA synthesis kit II (Exiqon, Denmark) 
according to the manufacturer’s instructions with the 
addition of one spike-in (UniSp6) to the RT reaction 
(Supplementary Material and Methods). 
Computational and statistical analyses
Raw reads quality-check, adapter clipping and 
mapping was performed as in [32]. After reads mapping, a 
matrix of integer values called count matrix was created. 
The value in the i-th row and the j-th column of the 
matrix reports how many reads have been unambiguously 
assigned to mature miRNA i in the sample j. 
The unwanted variation present in the data (e.g. batch 
effects) was estimated using the functions implemented in 
the SVA package [33](details in Supplementary Material 
and Methods).
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miRNA expression levels were measured in cancer 
subtypes (MIBC, NMIBC G1 + G2 and NMIBC G3) 
versus controls. Candidate miRNAs were selected by a 
tailored pipeline adapted from [34]. In details, two statistical 
methods, both running on the original miRNA counts 
matrix, were applied: (1) identification of differentially 
expressed miRNAs by DESeq2 Bioconductor’s package 
[35]; (2) computation of a regression model in which single 
variable levels (i.e. individual miRNA expression levels) are 
used to predict the class label (i.e. BC patients or controls) 
of each subject (predictive power calculation [36]).
From the first method, the candidate miRNAs 
(DEmiRNAs) were those associated with adjusted False 
Discovery Rate (FDR) ≤0.05 and the mean read count 
≥300. From the latter method, the candidate miRNAs 
(PPmiRNAs) were associated with a predictive power 
≥0.70. Due to the still high number of resulting putative 
candidate miRNAs for the Replica/Validation, an inspection 
of the plot counts of miRNAs across the classes (cancer 
and healthy sample) was also performed. Finally, miRNAs 
resulting relevant from the literature were also considered. 
Details in Supplementary Material and Methods.
Endogenous control for qPCR normalization were 
identified adapting the pipeline developed by Eisenberg 
and Levanon [14]. Briefly, miRNAs from NGS data 
were selected considering the individual raw count and 
according to the following criteria: 1) at least 2 reads for 
each sample; 2) a log2 standard deviation value < 12; 3) a 
log2 fold change ranging between –4 and 7.
Delta Ct (DCt) values were obtained by normalizing 
the data to the identified endogenous controls selected 
from NGS outcomes. Differential miRNA expression 
levels (expressed as fold-change and calculated as log2-
DDCt) between BC subtypes and controls were assessed by 
logistic regression adjusting for age and smoking. Results 
with p-value < 0.05 were deemed statistically significant 
(see Supplementary Material and Methods).
miRNA target genes were retrieved by miRWalk2.0 
database [37]. EnrichR was used for gene ontological 
analysis and pathway enrichment [38, 39]. The open-
access dataset of MIBC individuals from TCGA was also 
used for comparative analysis. All computational and 
statistical analyses are detailed in Supplementary Material 
and Methods.
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